1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSickle Cell Disease Clinical Trials is sponsored by National Institute of Health (NIH). Funds clinical trials aimed at evaluating new treatments for sickle cell disease.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Sickle Cell Disease: Research, Programs, and Progress | NHLBI, NIH Sickle Cell Disease: Research, Programs, and Progress Sickle Cell Disease: Research, Programs, and Progress Sickle cell disease affects approximately 100,000 Americans, many of whom are African American, and more than 8 million people worldwide.
Sickle cell disease (SCD) research nationwide Discover how the Division of Blood Diseases and Resources supports sickle cell disease research and clinical centers across the nation. SCD Knowledge and Practices Among Healthcare Providers Results from a national survey show awareness and knowledge gaps specific to the care of patients with sickle cell disease.
Healthy Living with Sickle Cell Disease Learn tips to support your mental and physical health. The Blood Diseases & Disorders Education Program offers a variety of educational resources to help increase awareness and understanding about sickle cell disease.
Learn About Sickle Cell Disease Learn About Genetic Therapies Sickle Cell Awareness Month Resources Today’s Faces of Sickle Cell Disease Read inspiring stories of people living with sickle cell disease, their loved ones, clinicians, and the researchers whose work offers hope for a cure.
Meet these inspiring faces of sickle cell disease Leading the Cure Sickle Cell Initiative See how NHLBI-led research is paving the way to a cure for sickle cell disease.
Cure Sickle Cell Initiative Blood Diseases & Disorders Education Program A national health education program that aims to bring greater visibility to blood diseases and disorders like anemia, sickle cell disease and others, their diagnosis, treatment and management, and blood safety by translating research for patients and professionals. Blood Disorders and Blood Safety The NHLBI is a global leader in blood-related research.
Learn about NHLBI-supported research on blood disorders, including sickle cell disease, blood safety, transfusion medicine, and more. Joining an NHLBI Sickle Cell Clinical Trial Find out if you or someone you love is eligible to participate in an NHLBI clinical trial for sickle cell disease. Sickle Cell Research at the NHLBI Learn about ongoing research from NHLBI labs in the Sickle Cell Branch.
Learn more about active NHLBI-funding opportunity announcements for sickle cell disease. Advancing Sickle Cell Treatments from Lab to Clinical Practice Read how the NHLBI Implementation Science Branch helps translate genomic research and therapies into real-world practices. Learn how COVID-19 affect the blood.
Shedding light on a neglected form of sickle cell disease Sickle cell disease (SCD) is a group of painful and life-threatening genetic disorders that affect hemoglobin, the major protein that carries oxygen in red blood cells. It occurs in nearly 100,000 people in the... Sickle Cell in Focus 2024 The 17th annual Sickle Cell in Focus (SCiF) conference will be held in a hybrid format from September 19th to September 20th, 2024, with ...
1-877-NHLBI4U (1-877-645-2448) Open Monday through Friday, 8:30 a. m. to 5:00 p.
m. Eastern time (closed on Federal holidays). For access to free Telecommunications Relay Services (TRS), dial 7-1-1 on your telephone.
NHLBI Center for Health Information
According to the current listing, eligibility includes: Nonprofits, Universities, State/local governments. Confirm the full requirements in the official notice before applying.
Sickle Cell Disease Clinical Trials is funded by National Institute of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
HEAL Initiative STTR Program (Phase 1 and Phase 2 grants) is sponsored by National Institute of Health (NIH). This Small Business Technology Transfer (STTR) program provides funding for small businesses developing medical technologies, tools, or devices related to pain management. Projects must involve a partnership with a research or educational institution for clinical trials.
NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award is sponsored by National Institute of Health (NIH). This funding opportunity supports early-career scientists with strong research skills and experience in technology discovery who are interested in entrepreneurship and transitioning into the industry. It is a Small Business Innovation Research (SBIR) Grant.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article